Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California.
Biol Blood Marrow Transplant. 2019 Feb;25(2):193-203. doi: 10.1016/j.bbmt.2018.09.022. Epub 2018 Sep 22.
Acute graft-versus-host disease (aGVHD) is an immune-mediated reaction that can occur after hematopoietic stem cell transplantation in which donor T cells recognize the host antigens as foreign, destroying host tissues. Establishment of a tolerogenic immune environment while preserving the immune response to infectious agents is required for successful bone marrow transplantation. Pregnancy-specific glycoprotein 1 (PSG1), which is secreted by the human placenta into the maternal circulation throughout pregnancy, likely plays a role in maintaining immunotolerance to prevent rejection of the fetus by the maternal immune system. We have previously shown that PSG1 activates the latent form of transforming growth factor β1 (TGF-β), a cytokine essential for the differentiation of tolerance-inducing CD4FoxP3 regulatory T cells (Tregs). Consistent with this observation, treatment of naïve murine T cells with PSG1 resulted in a significant increase in FoxP3 cells that was blocked by a TGF-β receptor I inhibitor. We also show here that PSG1 can increase the availability of active TGF-β in vivo. As the role of CD4FoxP3 cells in the prevention of aGVHD is well established, we tested whether PSG1 has beneficial effects in a murine aGHVD transplantation model. PSG1-treated mice had reduced numbers of tissue-infiltrating inflammatory CD3 T cells and had increased expression of FoxP3 in T cells compared with vehicle-treated mice. In addition, administration of PSG1 significantly inhibited aGVHD-associated weight loss and mortality. On the other hand, administration of PSG1 was less effective in managing aGVHD in the presence of an alloimmune reaction against a malignancy in a graft-versus-leukemia experimental model. Combined, this data strongly suggests that PSG1 could be a promising treatment option for patients with aGVHD following bone marrow transplantation for a nonmalignant condition, such as an autoimmune disorder or a genetic immunodeficiency.
急性移植物抗宿主病(aGVHD)是一种免疫介导的反应,可发生在造血干细胞移植后,其中供体 T 细胞将宿主抗原识别为外来物,从而破坏宿主组织。为了成功进行骨髓移植,需要建立一个耐受免疫的环境,同时保留对感染因子的免疫反应。妊娠特异性糖蛋白 1(PSG1)在整个怀孕期间由人胎盘分泌到母体循环中,可能在维持免疫耐受方面发挥作用,以防止母体免疫系统排斥胎儿。我们之前已经表明,PSG1 激活转化生长因子 β1(TGF-β)的潜伏形式,TGF-β 是诱导耐受的 CD4FoxP3 调节性 T 细胞(Tregs)分化所必需的细胞因子。与这一观察结果一致,用 PSG1 处理幼稚的小鼠 T 细胞会导致 FoxP3 细胞显著增加,而 TGF-β 受体 I 抑制剂则阻断了这种增加。我们还在这里表明,PSG1 可以增加体内活性 TGF-β 的可用性。由于 CD4FoxP3 细胞在预防 aGVHD 中的作用已得到充分证实,我们测试了 PSG1 在小鼠 aGHVD 移植模型中是否具有有益作用。与载体处理的小鼠相比,PSG1 处理的小鼠的组织浸润性炎症性 CD3 T 细胞数量减少,并且 T 细胞中 FoxP3 的表达增加。此外,PSG1 的给药显著抑制了与 aGVHD 相关的体重减轻和死亡率。另一方面,在针对移植物抗白血病实验模型中的恶性肿瘤的同种免疫反应存在的情况下,PSG1 的给药对管理 aGVHD 的效果较差。综合来看,这些数据强烈表明,PSG1 可能是骨髓移植后患有非恶性疾病(如自身免疫性疾病或遗传性免疫缺陷)的 aGVHD 患者的一种有前途的治疗选择。